TABLE 2.

Mendelian randomization of risks of osteoarthritis, knee osteoarthritis, and hip osteoarthritis using statins.

Exposure	Outcome	Mendelian randomized analysis method	Number of ultimately included single-nucleotide polymorphisms	OR (95%CI)	P
Statins	Osteoarthritis	Inverse-variance weighting method	90	0.998 (0.996–0.999)	0.01
		Mendelian randomized Egger intercept	90	0.997 (0.995–1.000)	0.089
		Weighted median	90	0.997 (0.995–0.999)	0.009
		Weighted median estimator	90	0.997 (0.995–1.000)	0.058
		Simple median	90	0.995 (0.991–0.999)	0.023
	Knee osteoarthritis	Inverse-variance weighting method	101	0.964 (0.940–0.989)	0.005
		Mendelian randomized Egger intercept	101	0.968 (0.930–1.000)	0.121
		Weighted median	101	0.943 (0.912–0.975)	<0.001
		Weighted median estimator	101	0.957 (0.925–0.990)	0.014
		Simple median	101	0.992 (0.914–1.077)	0.85
	Hip osteoarthritis	Inverse-variance weighting method	101	0.928 (0.901–0.955)	<0.001
		Mendelian randomized Egger intercept	101	0.909 (0.869–0.951)	<0.001
		Weighted median	101	0.923 (0.882–0.965)	<0.001
		Weighted median estimator	101	0.923 (0.889–0.959)	<0.001
		Simple median	101	0.901 (0.833–0.975)	0.011